470-476WTO adopted the waiver solution in compulsory
licensing, beginning from the Doha Declaration to the amendment of TRIPS
Agreement, to facilitate access to medicine to the countries lacking
manufacturing capacity. This article examines challenges faced by countries
while issuing compulsory licensing; waiver decision with regard to Article
31(f) and 31 (h) of TRIPS Agreement. The article further analyses the causes as
to why the waiver solution has not been as effective as it was hoped and
envisages an increase in its importance in the coming days